Exploring the Future Frontiers of Human Health, with Francois Nader
The President & CEO of NPS Pharmaceuticals predicts tremendous growth for the pharmaceutical industry in the coming years as new cures and treatments are developed.
Francois Nader, MD, has been President, Chief Executive Officer and a member of the Board of Directors of NPS Pharma since 2008. During his tenure, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on pioneering and delivering innovative therapies that transform the lives of patients with rare diseases worldwide.
Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS Pharma in 2006 as chief medical and commercial officer and was promoted to chief operating officer in 2007. Previously, he was a venture partner at Care Capital. Dr. Nader served on the North America Leadership Team of Aventis and its predecessor companies and held a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Prior, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.
Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee. Dr. Nader is the immediate past chair of the Board of Trustees for BioNJ, New Jersey’s trade organization representing the biotechnology industry. He is also a Board member of the Biotechnology Industry Organization (BIO), the New Jersey Chamber of Commerce, Trevena, Inc., Clementia Pharmaceuticals, Inc. and Acceleron Pharma Inc. In 2013, Dr. Nader was recognized as the Ernst and Young National Life Science Entrepreneur of the Year.
Francois Nader: I think we have tremendous, tremendous growth, tremendous potential in exploring the frontier of human beings. We are just at the very, very beginning of a very exciting adventure. And think of diseases as common cold, right. There is nothing terribly unusual about common cold, right. Yet we don’t have a cure for common cold yet, okay. Which is kind of ironic, right. Which means that innovation could be very small for small things like common cold or big things like Alzheimer’s and diabetes. We have multiple products for the diabetes today. We don’t have a cure for diabetes yet. Actually if you add Alzheimer’s and diabetes it could bankrupt our healthcare system. Yet we don’t have a cure for diabetes and we don’t know how to deal with Alzheimer’s yet. So if I look at the future a couple of things will happen.
One, we have phenomenal tools that will enable us to diagnose and to be more specific in better understanding the mechanism of virtually any disease. And the second aspect would be based on that we can start now, charter the road to better understanding the brain which will be a huge advancement.
We don’t know much about the brain. We know a few things here and there. But the brain is a huge unknown scientifically still. We don’t have a lot of tools yet to better understand how we think, the memory and everything related to our behavior. So the brain will be probably the next frontier.
But we should not forget that we have still about 6,000 rare diseases that do not have a treatment so we have a lot of work to do. And we cannot do it alone. I mean money and investment is one thing but we need to continue working on the framework of the regulatory agencies and how we can partner with the regulators to have a clearer path forward to having the new drugs approved.
The biggest challenge we face is science is moving so fast that the regulators have to catch up. They have to catch up to understand and catch up even more to regulate us which is a very daunting challenge and I really believe that the regulators are doing the right things in most of the cases. But at the same time I can only see the challenges that they have to better understand how the science is progressing. And you hear every day about the genomes and our understanding of the genomes. I mean this is absolutely flabbergasting the progress we’ve made over the last 15 years in better understanding the inner mechanics of how we work. And from there will come new medications, will come new cures, new treatments.
The President & CEO of NPS Pharmaceuticals predicts tremendous growth for the pharmaceutical industry in the coming years as new cures and treatments are developed. He also speaks about the broad scope of pharmaceutical research. The coming decades will see advances in treating minor issues such as the common cold, as well as broad steps forward in the fight against the frightening destruction of Alzheimer's disease.
The biggest challenge moving forward, says Nader, is for regulators to keep up with the radical growth and achievements sure to come. Policy and science need to remain on the same page in order to maximize the positive effects of research.
Malcolm Gladwell teaches "Get over yourself and get to work" for Big Think Edge.
- Learn to recognize failure and know the big difference between panicking and choking.
- At Big Think Edge, Malcolm Gladwell teaches how to check your inner critic and get clear on what failure is.
- Subscribe to Big Think Edge before we launch on March 30 to get 20% off monthly and annual memberships.
Does believing in true love make people act like jerks?
- Ghosting, or cutting off all contact suddenly with a romantic partner, is not nice.
- Growth-oriented people (who think relationships are made, not born) do not appreciate it.
- Destiny-oriented people (who believe in soulmates) are more likely to be okay with ghosting.
Archeologists had been doubtful since no such ship had ever been found.
- In 450 BCE, Greek historian Herodotus described a barge that's never been found.
- When the ancient port of Thonis-Heracleion was discovered, some 70 sunken ships were found resting in its waters.
- One boat, Ship 17, uncannily matches the Herodotus' description.
SMARTER FASTER trademarks owned by The Big Think, Inc. All rights reserved.